PT-141 (Bremelanotide): The Peptide for Sexual Health — Mechanism, Dosing, and Research
PT-141 (Bremelanotide) is an FDA-approved melanocortin receptor agonist for sexual dysfunction. Learn about its unique mechanism, dosing protocols, and clinical evidence.
What Is PT-141?
PT-141, also known as bremelanotide, is a melanocortin receptor agonist that works through the central nervous system to enhance sexual desire and arousal. Unlike PDE5 inhibitors (Viagra, Cialis) which act on blood flow mechanics, PT-141 works on the brain's desire pathways — making it effective for both desire and arousal components of sexual function.
PT-141 was FDA-approved in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is also widely used off-label in men, where it has shown efficacy for both desire and erectile function, including in patients who don't respond to PDE5 inhibitors.
The peptide is derived from Melanotan II but has been modified to remove the tanning effects while retaining the sexual function properties. It acts on melanocortin-4 receptors (MC4R) in the hypothalamus, which are involved in sexual behavior, arousal, and desire.
How PT-141 Works: A Unique Mechanism
PT-141's mechanism is fundamentally different from all other sexual health medications on the market. PDE5 inhibitors work downstream on vascular smooth muscle to improve blood flow. PT-141 works upstream in the brain, activating melanocortin pathways that modulate sexual desire and arousal.
The melanocortin-4 receptor (MC4R) in the hypothalamus plays a central role in sexual behavior across mammals. When activated by PT-141, MC4R triggers downstream signaling cascades that increase dopaminergic activity in brain regions associated with sexual motivation and reward.
This central mechanism means PT-141 can address the desire component of sexual dysfunction — something that PDE5 inhibitors cannot do. For many patients, especially women with HSDD, the issue is not mechanical but motivational. PT-141 addresses this root cause.
PT-141 also has mild effects on erectile function through central pathways, making it a versatile option for men who want both desire enhancement and functional support. Some physicians combine PT-141 with low-dose PDE5 inhibitors for a comprehensive approach.
Dosing Protocol
PT-141 is administered as a subcutaneous injection approximately 45 minutes before anticipated sexual activity. The typical dose is 1.75mg, though physicians may start at lower doses (0.5-1mg) and titrate upward based on response.
Unlike daily medications, PT-141 is used on an as-needed basis. The recommended maximum frequency is 8 doses per month, with no more than one dose per 24-hour period. This on-demand usage pattern makes it practical for patients who don't want daily medication.
Side effects include nausea (most common, affecting approximately 40% of users), flushing, headache, and a transient increase in blood pressure. Nausea is typically mild to moderate and lasts 1-2 hours. Taking an antiemetic 30 minutes before PT-141 can reduce this side effect.
PT-141 pairs well with testosterone optimization protocols for men experiencing both low desire and low testosterone. The combination addresses both hormonal and neurological components of sexual health. Explore PT-141 dosing in our free Dose Calculator at longevityai.io.
Clinical Evidence
The RECONNECT Phase 3 trials demonstrated that PT-141 significantly increased sexual desire and reduced distress related to low desire in premenopausal women with HSDD. Patients reported improvements in desire, arousal, and overall sexual satisfaction.
In male studies, PT-141 showed efficacy in men with erectile dysfunction who did not respond to sildenafil (Viagra). A study published in the Journal of Sexual Medicine showed that PT-141 improved erection quality in 33% of sildenafil non-responders — a population with very limited options.
Research also suggests PT-141's effects improve with repeated use, unlike PDE5 inhibitors which show consistent efficacy from first use. Some patients report optimal response after 3-5 uses, suggesting a priming or sensitization effect on melanocortin pathways.
The safety profile is well-established through clinical trials and post-marketing surveillance. PT-141 should not be used in patients with uncontrolled hypertension or cardiovascular disease due to its transient blood pressure effects. Learn more in our Compound Wiki.